PIK3CA and breast cancer: This co-targeting approach is particularly promising in tumors where both MAPK and PI3K pathways are activated.​ These findings underscore the importance of MAPK3 activation in breast cancer progression and the potential for MAPK pathway inhibitors like trametinib as viable treatment options (72).